Presentation on theme: "Brandeis University Health Plan Performance on HEDIS Antidepressant Medication Management: Relationship with Organizational Characteristics Brandeis University."— Presentation transcript:
Brandeis University Health Plan Performance on HEDIS Antidepressant Medication Management: Relationship with Organizational Characteristics Brandeis University Constance M. Horgan, Sc.D. (Project Director) Elizabeth Levy Merrick, Ph.D., M.S.W. NCQA: Sarah Hudson Scholle, Dr. P.H., M.P.H. Sarah Shih, M.P.H. Center for Behavioral Health Schneider Institute for Health Policy Heller School for Social Policy and Management Support provided by the Robert Wood Johnson Foundation Depression in Primary Care Initiative
Objective Determine whether performance and improvement over time on three antidepressant medication management (AMM) measures in HEDIS differ by how health plans organize, finance, and administer behavioral health care.
Context HEDIS AMM measures overall are low compared to other HEDIS measures AMM measures are generally not improving over time (unlike other measures) Most privately insured individuals are in managed care Need to learn what health plan features are associated with better performance
Health Plan Domains Organization Provider Consumer
Research Design Overview Linkage of two datasets: Brandeis Health Plan Survey and NCQAs HEDIS and CAHPS data Analyzing relationships between key plan characteristics and performance on AMM measures Both cross-sectional and longitudinal (1999 to 2003) analyses
Data and Sample Brandeis Survey: 2003 health plan survey on alcohol, drug, and mental health services. Nationally representative, linked to 60 Community Tracking Study market areas. N = 368 (812 products). Response rate = 83%. NCQA: 2003 health plan participants in HEDIS. N = 300. Study Sample: All health plans present in both datasets. N = 183 plans, covering 361 HMO and POS products.
Analytic Approach Describe health plans 2003 performance on the three HEDIS AMM measures and relationship with key plan characteristics Conduct multivariate analysis to control for effects of other health plan and market variables.
Effective Acute Phase Treatment Mean = 59.5% 10 th percentile = 53.6% 90 th percentile = 66.2% Percentage of eligible members who received effective acute phase treatment after a new episode of depression by remaining on antidepressant medication during the first 12 weeks following diagnosis
Effective Continuation Phase Treatment Mean = 42.9% 10 th percentile = 37.8% 90 th percentile = 50.5% Percentage of members who received effective continuation phase treatment by remaining on antidepressant medication continuously in the 6 months after the initial diagnosis and treatment.
Optimal Practitioner Contact Percentage of eligible members who received at least 3 follow-up office visits with PCP or mental health provider in the 12-week acute treatment phase after diagnosis of depression and prescription of antidepressant medication. Mean =22.1% 10 th percentile=12.6% 90 th percentile=36.8%
Organization Domain Product Type HMO POS Contracting Arrangement Specialty Comprehensive/Internal 50% 80% 20% Depression Disease Management Program 47% Degree of PCP/BH Coordination (0-6 methods) 3.0
Provider Domain Provide training on depression guidelines74% Provide feedback on individual performance re: guideline adherence 36% Provide feedback on network performance re: guideline adherence 20% Degree of support provided for guideline adherence (0 – 3 activities) 1.3 Plan allows PCP to bill for psychiatric procedure codes 38% MH screening required by plan36%
Consumer Domain High Cost Sharing for MH Outpatient Visits (> 20% co-insurance or > $20 co-pay) 33% Pharmacy Tier 2 Cost Sharing (mean)$22 Access to new SSRIs without restrictions on Tier 2 (0-4 medications) 2.5 Direct Access – No MH Gatekeeping39%
Rate of Effective Acute Phase Treatment a = P <.01 b = P <.05 Adjusted R 2 = 0.53 Regression model included all variables in the three domains, as well as enrollment, tax status and region. Only significant domain variables shown. High MH Cost Sharing a Disease Management a Degree of PCP/BH Coordination b Feedback Individual Performance a PCP Psychiatric Billing a MH Screening b Specialty Contract a SSRI Choice b Direct Specialty Access b
Rate of Effective Continuation Phase Treatment a = P <.01 Adjusted R 2 = 0.45 Regression model included all variables in the three domains, as well as enrollment, tax status and region. Only significant domain variables shown. Specialty Contract a Feedback-Individual Performance a PCP Psychiatric Billing a High MH Cost Sharing a Direct Specialty Access a
Rate of Optimal Provider Contact a = P <.01 b = P <.05 Adjusted R 2 = 0.49 Regression model included all variables in the three domains, as well as enrollment, tax status and region. Only significant domain variables shown. Degree of PCP/BH Coordination a Product Type HMO b Feedback Individual Performance a MH Screening b Tier 2 Cost Sharing a
Conclusions Patient cost sharing and choice of SSRIs affect HEDIS AMM performance Individual feedback to providers helps Some approaches geared towards improving quality seem to do so (disease management) Others (e.g., PCP/BH coordination) raise more questions